Paul M. Barr
Medical Director, Cancer Center Clinical Trials Office · Cancer Center
Credentials: · · · · ·
History
- Present
Cancer Center Clinical Trials Office
- Present
SMD
- Present
Cancer Center
Research
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
New England Journal of Medicine · 2014 · 1,369 citations
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
New England Journal of Medicine · 2015 · 1,331 citations
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Nature Medicine · 2015 · 979 citations
44 papers
26 papers
24 papers
24 papers
23 papers
23 papers
22 papers
- SO
22 papers
Grants
- 2019–2032
Rochester Network Lead Academic Participating Site
National Cancer Institute · UG1
Contact PI · $6.9M · University of Rochester
Clinical trials
- 2019–2023
Principal investigator · Completed · Phase 2
University of Rochester
- 2018–2027
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
- 2011–2015
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
- 2011–2014
Imexon for Relapsed Follicular and Aggressive Lymphomas
Principal investigator · Completed · Phase 2
University of Rochester